Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia.

0%, respectively; 95% confidence interval, 9·48, 57·19) (Table 2 ), although this treatment difference did not reach statistical significance ( N = 22; P = 0·1348) due to the small number of patients using ITP medications at baseline.

also in 111,027 other papers